ArticleNature biotechnology2024
AIntibody: an experimentally validated in silico antibody discovery design challenge.
Abstract readLetter
In one paragraph
Article in Nature biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Article
- ASD: antigen-specific antibody database.mAbs · 2026Article
- IMGT-NC Engineered Variants of INN Therapeutic IG or Antibodies and Related IgSF Proteins (TR, FPIA and CPCA): Bridging Sequences, Structures and Functions for AI.Biomolecules · 2026Review
- A blinded, prospective benchmark of in silico antibody discovery anchored to experimental affinity and developability.Nature biotechnology · 2026Article
- MAHLER: Integrating Metadynamics and Inverse Folding to Predict Antibody-Antigen Kinetics.bioRxiv : the preprint server for biology · 2026Article
- In-Culture Antibody Capture Using Transient CHO Expression Systems.Bio-protocol · 2026Article
- From Single Cells to Silicon: Emerging Technologies Transforming Monoclonal Antibody Discovery.Antibodies (Basel, Switzerland) · 2026Review
- How new approach methods are reshaping virology research.Journal of virology · 2026Review
- IMGTAntibodies (Basel, Switzerland) · 2026Review
- NanoBondy Reaction through NeissLock Anhydride Allows Covalent Immune Cell Decoration.Bioconjugate chemistry · 2026Article
- Fitness Landscape for Antibodies 2: Benchmarking Reveals That Protein AI Models Cannot Yet Consistently Predict Developability Properties.bioRxiv : the preprint server for biology · 2025Article
- Article
- Article
- A Robust, High-Titer, Semi-Automated, and In-Culture Antibody-Capturing Transient CHO Platform Technology.Antibodies (Basel, Switzerland) · 2025Article
- Investigating the volume and diversity of data needed for generalizable antibody-antigen ΔΔG prediction.Nature computational science · 2025Article
- Applying computational protein design to therapeutic antibody discovery - current state and perspectives.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors.
M Frank ErasmusSpecifica LLC, an IQVIA business, Santa Fe, USA. mfrank.erasmus@iqvia.com.ORCID http://orcid.org/0000-0002-8046-5048
Laura SpectorSpecifica LLC, an IQVIA business, Santa Fe, USA.ORCID http://orcid.org/0000-0002-3965-9115
Fortunato FerraraSpecifica LLC, an IQVIA business, Santa Fe, USA.
Roberto DiNiroSpecifica LLC, an IQVIA business, Santa Fe, USA.
Thomas J PohlSpecifica LLC, an IQVIA business, Santa Fe, USA.
Katheryn Perea-SchmittleSpecifica LLC, an IQVIA business, Santa Fe, USA.
Wei WangUniversity of California, San Diego, USA.ORCID http://orcid.org/0000-0003-4377-5060
Peter M TessierUniversity of Michigan, Ann Arbor, USA.
Crystal RichardsonGENEWIZ from Azenta Life Sciences, South Plainfield, USA.
Laure TurnerGENEWIZ from Azenta Life Sciences, South Plainfield, USA.
Sumit KumarGENEWIZ from Azenta Life Sciences, South Plainfield, USA.
Daniel BedingerCarterra, Salt Lake City, USA.ORCID http://orcid.org/0000-0001-5009-9369
Pietro SormanniUniversity of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-6228-2221
Monica L Fernández-QuinteroScripps Research Institute, San Diego, CA, USA.ORCID http://orcid.org/0000-0002-6811-6283
Andrew B WardScripps Research Institute, San Diego, CA, USA.ORCID http://orcid.org/0000-0001-7153-3769
Johannes R LoefflerScripps Research Institute, San Diego, CA, USA.
Olivia M SwansonScripps Research Institute, San Diego, CA, USA.ORCID http://orcid.org/0000-0001-8162-8358
Charlotte M DeaneUniversity of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-1388-2252
Matthew I J RaybouldUniversity of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-5663-5297
Andreas EversMerck KGaA, Darmstadt, Germany.ORCID http://orcid.org/0000-0003-4643-1941
Carolin SellmannMerck KGaA, Darmstadt, Germany.
Sharrol BachasEvolutionary Scale, San Francisco, USA.
Jeff RuffoloProfluent Bio, Berkeley, USA.ORCID http://orcid.org/0000-0002-3385-9191
Horacio G NastriIncyte, Inc, Wilmington, USA.
Karthik RameshIncyte, Inc, Wilmington, USA.
Jesper SørensenOpenEye, Cadence Molecular Sciences, Santa Fe, USA.
Rebecca Croasdale-WoodAstrazeneca, Cambridge, UK.
Oliver HijanoSanofi, Inc, Cambridge, USA.
Camila Leal-LopesSanofi, Inc, Cambridge, USA.
Melody ShahsavarianEli Lilly, San Diego, USA.
Yu QiuSanofi, Inc, Cambridge, USA.
Paolo MarcatiliNovo Nordisk, A/S, Bagsværd, Denmark.
Erik VernetNovo Nordisk, A/S, Bagsværd, Denmark.ORCID http://orcid.org/0000-0002-4175-1244
Rahmad AkbarNovo Nordisk, A/S, Bagsværd, Denmark.
Simon FriedensohnAlloy Therapeutics, Basel, Switzerland.
Rick WagnerBonito Biosciences, Waltham, USA.
Vinodh Babu KurellaTakeda, Inc, Cambridge, USA.
Shipra MalhotraTakeda, Inc, Cambridge, USA.ORCID http://orcid.org/0000-0002-2234-191X
Satyendra KumarTakeda, Inc, Cambridge, USA.
Patrick KidgerCradle Bio, Zürich, Switzerland.
Juan C AlmagroGlobalBio, Inc., Cambridge, MA, USA.
Eric FurfineMosaic Biosciences, Boulder, USA.
Marty StantonMosaic Biosciences, Boulder, USA.
Christilyn P GraffMosaic Biosciences, Boulder, USA.
Santiago David VillalbaBayer AG, Leverkusen, Germany.
Florian TomszakBayer AG, Leverkusen, Germany.
Andre A R TeixeiraInstitute for Protein Innovation, Boston, USA.
Elizabeth HopkinsSapidyne Instruments, Inc. & GmbH, Boise, USA.
Molly DovnerSapidyne Instruments, Inc. & GmbH, Boise, USA.
Sara D'AngeloSpecifica LLC, an IQVIA business, Santa Fe, USA.
Andrew R M BradburySpecifica LLC, an IQVIA business, Santa Fe, USA. andrew.bradbury@iqvia.com.
Funding
Identification of key regulators in rheumatoid arthritisR01AR065466 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, WANG, WEI · 2014 to 2024
$4.6MJoint-location specific pathogenic pathways in rheumatoid arthritisR01AR071321 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, WANG, WEI · 2018 to 2023
$1.7MNIAMS NIH HHS R01 AR065466NIAMS NIH HHS R01 AR071321
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.